|
1
|
Petty WJ and Paz-Ares L: Emerging
strategies for the treatment of small cell lung cancer: A review.
JAMA Oncol. 9:419–429. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ost DE, Jim Yeung SC, Tanoue LT and Gould
MK: Clinical and organizational factors in the initial evaluation
of patients with lung cancer: Diagnosis and management of lung
cancer, 3rd ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 143 (5 Suppl):e121S–e141S.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines), . Small Cell Lung Cancer. Version
3.2023. National Comprehensive Cancer Network; Fort Washington:
2022
|
|
5
|
Karim SM and Zekri J: Chemotherapy for
small cell lung cancer: A comprehensive review. Oncol Rev.
6:e42012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Noda K, Nishiwaki Y, Kawahara M, Negoro S,
Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, et
al: Irinotecan plus cisplatin compared with etoposide plus
cisplatin for extensive small-cell lung cancer. N Engl J Med.
346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lara PN Jr, Natale R, Crowley J, Lenz HJ,
Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR,
et al: Phase III trial of irinotecan/cisplatin compared with
etoposide/cisplatin in extensive-stage small-cell lung cancer:
Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol.
27:2530–2535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanna N, Bunn PA Jr, Langer C, Einhorn L,
Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, et
al: Randomized phase III trial comparing irinotecan/cisplatin with
etoposide/cisplatin in patients with previously untreated
extensive-stage disease small-cell lung cancer. J Clin Oncol.
24:2038–2043. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lima JP, dos Santos LV, Sasse EC, Lima CS
and Sasse AD: Camptothecins compared with etoposide in combination
with platinum analog in extensive stage small cell lung cancer:
Systematic review with meta-analysis. J Thorac Oncol. 5:1986–1993.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
Extensive-Stage Small-Cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide versus platinum-etoposide
in first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Owonikoko TK, Behera M, Chen Z, Bhimani C,
Curran WJ, Khuri FR and Ramalingam SS: A systematic analysis of
efficacy of second-line chemotherapy in sensitive and refractory
small-cell lung cancer. J Thorac Oncol. 7:866–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk
Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T:
Phase III trial comparing supportive care alone with supportive
care with oral topotecan in patients with relapsed small-cell lung
cancer. J Clin Oncol. 24:5441–5447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aix SP, Ciuleanu TE, Navarro A, Cousin S,
Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, et
al: Combination lurbinectedin and doxorubicin versus physician's
choice of chemotherapy in patients with relapsed small-cell lung
cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3
trial. Lancet Respir Med. 11:74–86. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zaremba A, Eggermont AMM, Robert C, Dummer
R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D and
Zimmer L: The concepts of rechallenge and retreatment with immune
checkpoint blockade in melanoma patients. Eur J Cancer.
155:268–280. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JM and Chen DS: Immune escape to
PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann
Oncol. 27:1492–1504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ
and Ji J: Resistance to PD-1/PD-L1 blockade cancer immunotherapy:
Mechanisms, predictive factors, and future perspectives. Biomark
Res. 8:352020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Latchman Y, Wood CR, Chernova T, Chaudhary
D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al:
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2:261–268. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bojko M, Węgrzyn K, Sikorska E, Kocikowski
M, Parys M, Battin C, Steinberger P, Kogut MM, Winnicki M,
Sieradzan AK, et al: Design, synthesis and biological evaluation of
PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation
for cancer therapy. Bioorg Chem. 128:1060472022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cerniglia M, Klepadlo M, Sheneman D and
Kim SS: Response to PD-1 inhibitor after progression on PD-L1
inhibitor in advanced HCC. BMJ Case Rep. 15:e2500092022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Liu T, Liu Q, Mu S, Tao H, Yang X,
Li Y, Xiong Q, Wang L and Hu Y: Rechallenge of immunotherapy beyond
progression in patients with extensive-stage small-cell lung
cancer. Front Pharmacol. 13:9675592022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qin S, Li J, Zhong H, Jin C, Chen L, Yuan
X, Fan Q, Chen K, Cao P, Xiao J, et al: Serplulimab, a novel
anti-PD-1 antibody, in patients with microsatellite
instability-high solid tumours: An open-label, single-arm,
multicentre, phase II trial. Br J Cancer. 127:2241–2248. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen
G, Ji Y, Dvorkin M, Shi J, Pan Z, et al: Effect of First-line
serplulimab vs placebo added to chemotherapy on survival in
patients with extensive-stage small cell lung cancer: The
ASTRUM-005 randomized clinical trial. JAMA. 328:1223–1232. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang T, Li W, Diwu D, Chen L, Chen X and
Wang H: Efficacy and safety of first-line immunotherapy plus
chemotherapy in treating patients with extensive-stage small cell
lung cancer: A Bayesian network meta-analysis. Front Immunol.
14:11970442023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen S, Zhang Z, Zheng X, Tao H, Zhang S,
Ma J, Liu Z, Wang J, Qian Y, Cui P, et al: Response efficacy of
PD-1 and PD-L1 inhibitors in clinical trials: A systematic review
and Meta-analysis. Front Oncol. 11:5623152021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kluger HM, Tawbi HA, Ascierto ML, Bowden
M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL,
et al: Defining tumor resistance to PD-1 pathway blockade:
Recommendations from the first meeting of the SITC immunotherapy
resistance taskforce. J Immunother Cancer. 8:e0003982020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events (CTCAE).
Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5×7.pdfNovember
19–20242017.
|
|
33
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mor V, Laliberte L, Morris JN and Wiemann
M: The karnofsky performance status scale. An examination of its
reliability and validity in a research setting. Cancer.
53:2002–2007. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baize N, Monnet I, Greillier L, Geier M,
Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et
al: Carboplatin plus etoposide versus topotecan as second-line
treatment for patients with sensitive relapsed small-cell lung
cancer: An open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 21:1224–1233. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zugazagoitia J and Paz-Ares L:
Extensive-stage small-cell lung cancer: First-line and Second-line
treatment options. J Clin Oncol. 40:671–680. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ott PA, Elez E, Hiret S, Kim DW, Morosky
A, Saraf S, Piperdi B and Mehnert JM: Pembrolizumab in patients
with Extensive-stage small-cell lung cancer: Results from the phase
Ib KEYNOTE-028 study. J Clin Oncol. 35:3823–3829. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pujol JL, Greillier L, Audigier-Valette C,
Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine
J, Otto J, et al: A Randomized non-comparative phase II study of
anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as
second-line therapy in patients with small cell lung cancer:
Results from the IFCT-1603 trial. J Thorac Oncol. 14:903–913. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ready NE, Ott PA, Hellmann MD,
Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA,
Moreno V, Atmaca A, et al: Nivolumab monotherapy and nivolumab plus
ipilimumab in recurrent small cell lung cancer: Results from the
CheckMate 032 randomized cohort. J Thorac Oncol. 15:426–435. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Choudhury NJ and Riely GJ: Serplulimab
with chemotherapy in Extensive-Stage SCLC. JAMA. 328:1205–1207.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuan Y, Adam A, Zhao C and Chen H: Recent
advancements in the mechanisms underlying resistance to PD-1/PD-L1
blockade immunotherapy. Cancers (Basel). 13:6632021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 19:1189–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang P, Zhang C, Li X, Chang C, Gan C, Ye
T and Cao D: Immunotherapy for gastric cancer: Advances and
challenges. Med Comm Oncol. 3:e922024.
|
|
45
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zitvogel L and Kroemer G: Targeting
PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology.
1:1223–1225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dingemans AC, Fruh M, Ardizzoni A, Besse
B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N,
Rudin CM, et al: Small-cell lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol.
32:839–853. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu H, Wang K, Jia R, Zeng ZX, Zhu M, Deng
YL, Xiong ZJ, Tang JN, Xie H, Wang Y, et al: Current Status in
rechallenge of immunotherapy. Int J Biol Sci. 19:2428–2442. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ou SH, Ziogas A and Zell JA: Prognostic
factors for survival in extensive stage small cell lung cancer
(ED-SCLC): The importance of smoking history, socioeconomic and
marital statuses, and ethnicity. J Thorac Oncol. 4:37–43. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Meng K and Lu H: Clinical application of
high-LET radiotherapy combined with immunotherapy in malignant
tumors. Precis Radiat Oncol. 8:42–46. 2024. View Article : Google Scholar : PubMed/NCBI
|
